NCT07070960View on ClinicalTrials.gov

A Study of Anti-BCMA CAR-T Therapy in Newly Diagnosed Myeloma Patients Who Are Transplant-ineligible

NANot yet recruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

July 15, 2025

Primary Completion Date

July 15, 2026

Study Completion Date

July 31, 2028

Conditions
Multiple MyelomaNewly Diagnosed
Interventions
BIOLOGICAL

CAR-T

The T cells are genetically modified to express a chimeric antigen receptor targeting BCMA and are infused after induction therapy at a target dose of ≥2.0×10\^6 cells/kg

All Listed Sponsors
lead

Xuzhou Medical University

OTHER